Into the great wide open: Balancing benefits and risks of greater research and clinical trials data transparency – University of Copenhagen

Forward this page to a friend Resize Print Bookmark and Share

Global Genes Local Concerns > News > Into the great wide op...

08 December 2015

Into the great wide open: Balancing benefits and risks of greater research and clinical trials data transparency

CIIR and Global Genes-Local Concerns member, Timo Minssen, will speak about the implications of greater research and clinical trials transparency December 11th 10 -11 h at the National Committee on Health Research Ethics.

Recent US and European initiatives reflect a growing policy consensus favoring greater clinical trials and research transparency. New legislation, publishers and industry-driven projects promote independent verification of drug data, which provides a better framework for international collaboration. Greater transparency also increases public trust in research results, drugs and industry and the possibility of facilitating large cross-border clinical trials. Yet, the costs and concerns associated with opening up research and clinical trial data are also significant—for patients (protection of personal data and patient privacy), for research (misuse of clinical trial data) and for technology transfer and commercialization (obstacles to IP protection and increased exposure to litigation). This presentation will discuss these issues from an interdisciplinary perspective in order to sketch out legal mechanism that could  be useful for unlocking and safe-guarding the full potential of greater transparency.